Search Within

Weinberg Fellows

  1. "Kathryn Arbour"
Formats
  1. Meeting Abstract (43)
  2. Journal Article (42)
  3. Editorial (2)
  4. Review (2)
Groups
  1. Department of Medicine (89)
  2. Hematology-Oncology Fellows (89)
  3. Solid Tumor Oncology Division (89)
  4. Thoracic Oncology (89)
  5. GSK Faculty (39)
  6. Radiology, Department of (34)

More Groups

People
  1. Kathryn Arbour (89)
  2. Gregory Riely (42)
  3. Matthew Hellmann (40)
  4. Hira Rizvi (32)
  5. Andrew Plodkowski (23)
  6. Charles Rudin (22)

More People

Years
  1. 2025 (5)
  2. 2024 (10)
  3. 2023 (8)
  4. 2022 (9)
  5. 2021 (11)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (11)
  3. Journal of Thoracic Oncology (11)
  4. Clinical Cancer Research (6)
  5. Cancer Research (4)
  6. Cancer Discovery (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (32)
  2. Elsevier Inc. (16)
  3. American Association for Cancer Research (13)
  4. Oxford University Press (13)
  5. Nature Publishing Group (4)
  6. Massachusetts Medical Society (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma
    Meeting Abstract

    Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with stereotactic radiosurgery
    Journal Article

    Gaeta, B.; Eichholz, J. E.; Walch, H.; Ilica, A. T.; Boe, L.; Kratochvil, L.; Yu, Y.; Gomez, D. R.; Imber, B. S.; Li, B. T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Punekar, S. R.; Hong, D. S.; Luo, J.; Ou, S. H. I.; Johnson, M. L.; Spira, A.; Garrido-Laguna, I.; Goldman, J. W.; Herzberg, B.; Saltos, A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
    Meeting Abstract

    Hochmair, M. J.; Arbour, K. C.; Negrao, M. V.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Leal, T. A.; Lindsay, C.; Lu, S.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
    Journal Article

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Ricciuti, B.; Digumarthy, S.; Alessi, J. V.; Gogia, P.; Pecci, F.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • RRAS and RRAS2 mutations are oncogenic drivers in lung cancer and are sensitive to the PAN-RAS inhibitor RMC-6236
    Meeting Abstract

    Pfeil, A. J.; Zhang, T.; Febres-Aldana, C. A.; Cheng, R.; Mattar, M. S.; Arbour, K.; Ladanyi, M.; Yang, S. R.; Somwar, R.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
    Meeting Abstract

    Rodon, J.; Jänne, P. A.; Leventakos, K.; George, B.; Henry, J. T.; Johnson, M. L.; Papadopoulos, K. P.; Batista, A. I.; Spira, C. P.; Zhao, Y.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
    Journal Article

    Skoulidis, F.; Araujo, H. A.; Do, M. T.; Qian, Y.; Sun, X.; Cobo, A. G.; Le, J. T.; Montesion, M.; Palmer, R.; Jahchan, N.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save